De Greef-Safft Anne sold $174K of BHE

De Greef-Safft Anne sold 2,116 shares of BENCHMARK ELECTRONICS INC (BHE) at $82.26 ($0.17M total) on 2026-08-11.

Original reporting
SEC EDGAR · De Greef-Safft Anne
Published Aug 12, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BHE
Neutral
medium confidence
Mentioned
$BHE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BHENeutralLow
01

Why it matters

This is a disclosed open-market sale by a director, which can marginally influence sentiment but does not provide new operational or financial information about BHE.

02

Market read

Traders may note insider selling as a minor sentiment datapoint, but there is no fundamental catalyst in the filing.

03

What to watch

Insider sales often cluster around scheduled liquidity events; without context on total holdings, prior sales, or compensation structure, the signal is weak.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-12, sale dated 2026-08-11

Background

The article is a SEC Form 4 insider transaction disclosure for Benchmark Electronics (BHE).

Company-level read

Ticker impact

$BHENeutralMedium confidence
Context

Benchmark Electronics director De Greef-Safft Anne sold 2,116 shares for about $174,062.16 at $82.26 on 2026-08-11.

Expected impact

Low likelihood of sustained price impact; any reaction is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider transaction, but it does not include new company fundamentals, guidance, or legal/contract events. The sale size is moderate and lacks a stated 10b5-1 plan, which can raise interpretation risk but still typically does not drive fundamentals.

Market effects

No clear sector read-through from a single director sale.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification or personal liquidity needs, and the absence of a disclosed 10b5-1 plan does not necessarily imply negative expectations.

Key entities

  • BENCHMARK ELECTRONICS INC

    Company whose director insider sale is disclosed on Form 4.

  • De Greef-Safft Anne

    Director who sold 2,116 shares at $82.26 on 2026-08-11.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BHEHighAI 8/10

What Benchmark Electronics (BHE) Said on Its Q3 Earnings Call

Benchmark Electronics (BHE) reported Q3 growth in four of five end markets, with Semi-Cap revenue up 30% YoY. The company expects continued growth in 2027. It raised its Q4 and full-year outlook, forecasting 19% YoY revenue growth at the midpoint. BHE is investing in capacity and managing supply-chain constraints.

$BHEHighAI 8/10

Benchmark Electronics (BHE) Q3 2026 Earnings Call Transcript

Benchmark Electronics (BHE) reported Q3 2026 revenue of $811M, up 19% YoY, with non-GAAP EPS of $0.84, up 35% YoY. The company raised its full-year revenue outlook to over $3B. Semi-Cap and AC&C sectors drove growth, while Medical and Industrial also showed improvement. BHE expects Q4 revenue between $815M and $855M, with non-GAAP EPS between $0.85 and $0.91.

$BHEMedAI 8/10

Benchmark Electronics Inc (BHE) (Q3 2026) Earnings Call Highlights: Record Revenue

Benchmark Electronics (BHE) reported Q3 2026 earnings with record revenue and raised guidance. Aerospace & Defense revenue declined 1% YoY, and supply chain challenges persist. Inventory rose 16% sequentially. CEO David Moezidis cited customer forecasts and program ramps for growth confidence. The company expects capacity to support growth through 2027 and targets earnings growth at 1.5-2x revenue growth. Medical sector remains strong, with growth extending into 2028.